Sarepta Therapeutics Aktie
WKN DE: A1J1BH / ISIN: US8036071004
21.05.2025 15:26:52
|
Sarepta Gets Clearance From UK's MHRA To Continue Dosing In ENVISION Study Of Elevidys In DMD
(RTTNews) - Sarepta Therapeutics, Inc. (SRPT) Wednesday said that the UK's Medicines & Healthcare products Regulatory Agency (MHRA) has given clearance to continue dosing in the ENVISION Study of its gene therapy Elevidys for the treatment of Duchenne Muscular Dystrophy.
ENVISION is a Phase 3 study of Elevidys in non-ambulatory and older ambulatory individuals with Duchenne.
In the U.S., Elevidys is approved for the treatment of Duchenne Muscular Dystrophy in patients aged 4 and above.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Sarepta Therapeutics Inc.mehr Nachrichten
05.05.25 |
Ausblick: Sarepta Therapeutics vermeldet Zahlen zum jüngsten Quartal (finanzen.net) |
Analysen zu Sarepta Therapeutics Inc.mehr Analysen
Aktien in diesem Artikel
Sarepta Therapeutics Inc. | 33,59 | 2,91% |
|